Kearney C A, Silverman W K
University of Nevada, Las Vegas 89154-5030, USA.
J Anxiety Disord. 1998 Mar-Apr;12(2):83-102. doi: 10.1016/s0887-6185(98)00005-x.
Given the increasing trend in clinical child psychology and psychiatry toward cost-effective and pharmacological treatment, a review of key factors that influence treatment outcomes in this area seems warranted. This is especially important for the rapidly changing area of childhood anxiety disorders. In this article, we look at different change producing procedures to illustrate the claim that pharmacological studies are not necessarily what they seem. Specifically, pharmacological outcome studies are classified and reviewed on the basis of varying "secondary" treatments described in method sections. Three groups and efficacy rates were determined: (a) pharmacotherapy only (42.83%), (b) pharmacotherapy plus general/supportive psychotherapy (27.74%), and (c) pharmacotherapy plus a behavior therapy component (65.28%). We also discuss the implications of these findings for research as well as other methodological and theoretical concerns regarding the reviewed articles. These concerns include (a) methods used to diagnose participants, (b) methods used to assess improvement, (c) emphasis on diagnostic categories, (d) exclusionary criteria and comorbidity, (e) participant attrition and follow-up, and (f) key developmental and social contextual variables.
鉴于临床儿童心理学和精神病学领域越来越倾向于采用具有成本效益的药物治疗,对影响该领域治疗效果的关键因素进行综述似乎很有必要。这对于快速变化的儿童焦虑症领域尤为重要。在本文中,我们审视不同的促成改变的程序,以说明药物研究未必如其表面所示。具体而言,药物治疗效果研究是根据方法部分所描述的不同“辅助”治疗进行分类和综述的。确定了三组及有效率:(a) 仅药物治疗 (42.83%),(b) 药物治疗加一般/支持性心理治疗 (27.74%),以及 (c) 药物治疗加行为治疗成分 (65.28%)。我们还讨论了这些研究结果对研究的启示,以及与所综述文章相关的其他方法学和理论问题。这些问题包括:(a) 用于诊断参与者的方法,(b) 用于评估改善情况的方法,(c) 对诊断类别的强调,(d) 排除标准和共病情况,(e) 参与者流失和随访,以及 (f) 关键的发育和社会背景变量。